Translational Haematology
Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy
Search for publications
Only original articles, editorials, guidelines.
-
Antic D, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D, Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R, Cuéllar-García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efstathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicinska E, Kater AP, Kersting S, Koren-Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Šimkovic M, Smirnova S, Špacek M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, Stamatopoulos K.
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
JOURNAL OF HEMATOLOGY & ONCOLOGY . 15(1): 116-116.
-
Castaño-Bonilla T, Barragán E, Sargas C, Sanz A, Algarra L, Herrera-Puente P, García-Boyero R, Barrios M, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Serrano-López J, Martínez-López J, Sayas-Lloris MJ, Olave MT, Riaza-Grau R, Castillo TB, Larrayoz MJ, Amigo R, Jiménez-Velasco A, Sánchez J, Ayala R, Blas C, Lainez D, Serrano-López J, Sanz MA, Alonso-Domínguez JM, Montesinos P.
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
DISEASE MARKERS . 2022: 3132941-3132941.
-
Vigón L, Galán M, Torres M, Martín-Galiano AJ, Rodríguez-Mora S, Mateos E, Corona M, Malo R, Navarro C, Murciano-Antón MA, García-Gutiérrez V, Planelles V, Martínez-Laso J, López-Huertas MR, Coiras M.
Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort.
Plos One . 17(8): .
-
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J.
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
SCIENTIFIC REPORTS . 12(1): 13057-13057. Number of citations: 3
-
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Haematologica . : .
-
Puig N, Agullo Roca C, Sanfeliciano TC, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos-Tamayo R, Iñigo Rodríguez B, Sureda A, Lakhwani S, de la Rubia Comos J, Gonzalez-Calle V, Cabañas V, Palomera L, Moraleda JMM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV.
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.
Blood . : .
-
Santaliestra M, Garrote M, Noya MS, Pérez-Encinas M, Senín A, Pérez-López R, Ferrer-Marín F, Carreño-Tarragona G, Caballero G, Magro E, Vélez P, Cortés Vázquez MÁ, Moretó A, Angona A, Pastor-Galán I, Guerra JM, García Hernández C, Mata MI, Stuckey R, Gómez-Casares MT, Fox L, Cuevas B, García-Gutiérrez V, Triguero A, Arellano-Rodrigo E, Hernández-Boluda JC, Alvarez-Larrán A.
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.
Leukemia . : .
-
Pastor-Galán I, Pereira A, Arellano-Rodrigo E, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Garrote M, Ferrer B, Pérez-Encinas M, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC.
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.
Leukemia . : .
-
Pérez-Lamas L, Díaz AS, Casterá EM, Soto MH, Coll AP, De Las Heras N, Cortes M, Tenza PV, Pacho MS, Magan AS, Angona A, Cervero C, de Paz R, Cuenca AS, Santaliestra M, Marín JL, Casado LF, García-Gutiérrez V.
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
ANNALS OF HEMATOLOGY . : .
-
Rodríguez-Mora S, Sánchez-Menéndez C, Bautista-Carrascosa G, Mateos E, Moreno-Serna L, Megías D, Cantón J, García-Gutiérrez V, Murciano-Antón MA, Cervero M, Spivak A, Planelles V, Coiras M.
Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV.
BIOCHEMICAL PHARMACOLOGY . 229: 116512-116512.
-
Melica G, Luna de Abia A, Shah GL, Devlin S, Corona M, Fein J, Dahi PB, Giralt SA, Lin RJ, Palomba ML, Parascondola A, Park J, Salles G, Saldia A, Scordo M, Shouval R, Perales MA, Seo SK.
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Transplantation And Cellular Therapy . : .
-
Valtis YK, Devlin SM, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I Dr, Schöder H, Bedmutha A, Boardman AP, Shah GL, Scordo M, Perales MA, Salles GA, Palomba ML, Shah UA, Park JH.
Cancer cachexia and weight loss prior to CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Blood Advances . : .
-
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, Vives S, Serrano J, Bernal T, Martínez-Sánchez P, Tormo M, Rodríguez-Medina C, Herrera-Puente P, Lavilla-Rubira E, Boluda B, Acuña-Cruz E, Cano I, Cáceres S, Ballesteros J, Falantes J, Martínez-Cuadrón D, Pérez-Simón JA, Montesinos P.
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
CANCER . : .